US-based Cornerstone Pharmaceuticals has started a Phase I clinical trial of its lead Altered Energy Metabolism Directed (AEMD) drug candidate CPI-613 to treat patients with relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL).

The trial is designed to evaluate CPI-613, in combination with bendamustine and rituximab, in these patients.

CPI-613 is a first-in-class anticancer compound designed to disrupt the altered energy-production pathways in cancer cells by targeting mitochondrial metabolism.

Cornerstone chief executive officer Steve Carchedi said: "Initiating this Phase I trial marks the fourth ongoing trial evaluating our lead compound CPI-613 in advanced haematologic malignancies and overall the eighth study being sponsored by notable, National Cancer Institute-designated comprehensive cancer center, Wake Forest Baptist Medical Center.

"The trial is designed to evaluate CPI-613, in combination with bendamustine and rituximab, in these patients."

"Furthermore, this study represents the continued interest in CPI-613 by the medical community as an unique approach to fighting cancer by blocking the energy producing pathways that support the growth and development of many cancer cells.

"We look forward to the active enrollment of B-cell Non-Hodgkin Lymphoma patients in this study as we seek to demonstrate the potential of our lead product candidate as part of a combination therapy."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sponsored by Wake Forest Baptist Medical Center and in collaboration with the National Cancer Institute, the single site, open label, dose-escalating Phase I trial is designed to establish the maximum tolerated dose of CPI-613 when used in combination with bendamustine and rituximab.

The company said that secondary outcomes including response rate, overall survival rate, disease control rate and progression-free survival will also be evaluated in the trial.

In clinical trials, chemotherapy drug ‘bendamustine’ has shown single agent activity in heavily pretreated patients with rituximab-refractory (resistant), indolent NHL, showing an overall response rate of about 77%.

The company said that rituximab, an immunotherapy agent, was the first monoclonal antibody approved for cancer treatment.

Rituximab targets a specific antigen called CD-20 found on most B-cell lymphomasii and has been shown to result in a 40-50% response rate in patients who relapse with indolent B-cell lymphomas.